Study of PBF-999 in Solid Tumour Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions

Cancer

Interventions

DRUG

PBF-999

Phosphodiesterase 10 inhibitor (PDE10i)

Trial Locations (1)

Vall d'Hebron institute of oncology (VHIO), Barcelona

All Listed Sponsors

collaborator

Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology (Hospitalet) (ICO)

UNKNOWN

lead

Palobiofarma SL

INDUSTRY

NCT03786484 - Study of PBF-999 in Solid Tumour Advanced Cancer | Biotech Hunter | Biotech Hunter